{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:49:55Z","timestamp":1793890195644,"version":"4.8.0"},"reference-count":183,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In 1999, 1 year after the approval of the first oral phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED), the first Princeton Consensus Conference was held to address the clinical management of men with ED who also had cardiovascular disease. These issues were readdressed in the second and third conferences. In the 13\u00a0years since the last Princeton Consensus Conference, the experience with PDE5 inhibitors is more robust, and recent new data have emerged regarding not only safety and drug\u2013drug interactions, but also a potential cardioprotective effect of these drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>In March 2023, an interdisciplinary group of scientists and practitioners met for the fourth Princeton Consensus Guidelines at the Huntington Medical Research Institutes in Pasadena, California, to readdress the cardiovascular workup of men presenting with ED as well as the approach to treatment of ED in men with known cardiovascular disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A series of lectures from experts in the field followed by Delphi-type discussions were developed to reach consensus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>Consensus was reached regarding a number of issues related to erectile dysfunction and the interaction with cardiovascular health and phosphodiesterase-5 inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>An algorithm based on recent recommendations of the American College of Cardiology and American Heart Association, including the use of computed tomography coronary artery calcium scoring, was integrated into the evaluation of men presenting with ED. Additionally, the issue of nitrate use was further considered in an algorithm regarding the treatment of ED patients with coronary artery disease. Other topics included the psychological effect of ED and the benefits of treating it; the mechanism of action of the PDE5 inhibitors; drug\u2013drug interactions; optimizing use of a PDE5 inhibitors; rare adverse events; potential cardiovascular benefits observed in recent retrospective studies; adulteration of dietary supplements with PDE5 inhibitors; the pros and cons of over-the-counter PDE5 inhibitors; non\u2013PDE5 inhibitor therapy for ED including restorative therapies such as stem cells, platelet-rich plasma, and shock therapy; other non\u2013PDE5 inhibitor therapies, including injection therapy and penile prostheses; the issue of safety and effectiveness of PDE5 inhibitors in women; and recommendations for future studies in the field of sexual dysfunction and PDE5 inhibitor use were discussed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Implications<\/jats:title>\n                    <jats:p>Algorithms and tables were developed to help guide the clinician in dealing with the interaction of ED and cardiovascular risk and disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Strengths and Limitations<\/jats:title>\n                    <jats:p>Strengths include the expertise of the participants and consensus recommendations. Limitations included that participants were from the United States only for this particular meeting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The issue of the intersection between cardiovascular health and sexual health remains an important topic with new studies suggesting the cardiovascular safety of PDE5 inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdad163","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T01:04:07Z","timestamp":1700096647000},"page":"90-116","source":"Crossref","is-referenced-by-count":59,"title":["Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health"],"prefix":"10.1093","volume":"21","author":[{"given":"Robert A","family":"Kloner","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Research Pasadena, Huntington Medical Research Institutes , CA 91105 , United States"},{"name":"Department of Medicine, Keck School of Medicine at University of Southern California , Los Angeles, CA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur L","family":"Burnett","sequence":"additional","affiliation":[{"name":"Department of Urology, Johns Hopkins University , Baltimore, MD , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Miner","sequence":"additional","affiliation":[{"name":"Men\u2019s Health Center, Miriam Hospital , Providence, RI , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Blaha","sequence":"additional","affiliation":[{"name":"Cardiology and Epidemiology, Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease , Baltimore, MD , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ganz","sequence":"additional","affiliation":[{"name":"Department of Medicine (PG); Department of Urology (TL, IDS); Department of Psychiatry and Behavioral Sciences, (RCR), University of California , San Francisco, San Francisco, CA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irwin","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Department of Sexual Medicine, Institute for Sexual Medicine , Alvarado Hospital, San Diego, CA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel N","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Sexual Medicine, Institute for Sexual Medicine , Alvarado Hospital, San Diego, CA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Kohler","sequence":"additional","affiliation":[{"name":"Mayo Clinic , Rochester, MN , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Lue","sequence":"additional","affiliation":[{"name":"Department of Medicine (PG); Department of Urology (TL , IDS); Department of Psychiatry and Behavioral Sciences, (RCR), , San Francisco, San Francisco, CA , United States"},{"name":"University of California , IDS); Department of Psychiatry and Behavioral Sciences, (RCR), , San Francisco, San Francisco, CA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin T","family":"McVary","sequence":"additional","affiliation":[{"name":"Center for Male Health, Stritch School of Medicine at Loyola University Medical Center , Maywood, IL , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Mulhall","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, NY , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon J","family":"Parish","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine , New York, NY , United States"},{"name":"Department of Medicine and Psychiatry White Plains, Westchester Behavioral Health Center , NewYork-Presbyterian Hospital, NY , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Sadeghi-Nejad","sequence":"additional","affiliation":[{"name":"Department of Urology NY, NYU Langone Grossman School of Medicine , NY , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sadovsky","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, SUNY Downstate Health Sciences University , Brooklyn, NY , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira D","family":"Sharlip","sequence":"additional","affiliation":[{"name":"Department of Medicine (PG); Department of Urology (TL , IDS); Department of Psychiatry and Behavioral Sciences, (RCR), , San Francisco, San Francisco, CA , United States"},{"name":"University of California , IDS); Department of Psychiatry and Behavioral Sciences, (RCR), , San Francisco, San Francisco, CA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond C","family":"Rosen","sequence":"additional","affiliation":[{"name":"Department of Medicine (PG); Department of Urology (TL , IDS); Department of Psychiatry and Behavioral Sciences, (RCR), , San Francisco, San Francisco, CA , United States"},{"name":"University of California , IDS); Department of Psychiatry and Behavioral Sciences, (RCR), , San Francisco, San Francisco, CA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,26]]},"reference":[{"issue":"1","key":"2024020509071492300_ref1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.sxmr.2018.06.005","article-title":"The serendipitous story of sildenafil: an unexpected oral therapy for erectile dysfunction","volume":"7","author":"Goldstein","year":"2019","journal-title":"Sex Med Rev"},{"issue":"2","key":"2024020509071492300_ref2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0002-9149(00)00896-1","article-title":"Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton consensus panel","volume":"86","author":"DeBusk","year":"2000","journal-title":"Am J Cardiol"},{"issue":"12b","key":"2024020509071492300_ref3","doi-asserted-by":"crossref","first-page":"85m","DOI":"10.1016\/j.amjcard.2005.12.018","article-title":"Sexual dysfunction and cardiac risk (the second Princeton consensus conference)","volume":"96","author":"Kostis","year":"2005","journal-title":"Am J Cardiol"},{"issue":"8","key":"2024020509071492300_ref4","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.mayocp.2012.06.015","article-title":"The Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular disease","volume":"87","author":"Nehra","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2024020509071492300_ref5","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.sxmr.2018.03.008","article-title":"Cardiovascular safety of phosphodiesterase type 5 inhibitors after nearly 2 decades on the market","volume":"6","author":"Kloner","year":"2018","journal-title":"Sex Med Rev"},{"issue":"6","key":"2024020509071492300_ref6","doi-asserted-by":"crossref","first-page":"774","DOI":"10.7326\/M21-3445","article-title":"Adverse events associated with Coprescription of phosphodiesterase type 5 inhibitors and oral organic nitrates in male patients with ischemic heart disease: a case-crossover study","volume":"175","author":"Holt","year":"2022","journal-title":"Ann Intern Med"},{"issue":"9","key":"2024020509071492300_ref7","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jsxm.2021.06.010","article-title":"Cardiovascular outcome risks in patients with erectile dysfunction co-prescribed a phosphodiesterase type 5 inhibitor (PDE5i) and a nitrate: a retrospective observational study using electronic health record data in the United States","volume":"18","author":"Nunes","year":"2021","journal-title":"J Sex Med"},{"issue":"10","key":"2024020509071492300_ref8","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2024020509071492300_ref9","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/ijcp.12864","article-title":"In memoriam: Dr Graham Jackson, 1947-2016","volume":"70","author":"Cooper","year":"2019","journal-title":"Int J Clin Pract"},{"issue":"18","key":"2024020509071492300_ref10","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jama.1996.03530420033032","article-title":"Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. Determinants of myocardial infarction onset study investigators","volume":"275","author":"Muller","year":"1996","journal-title":"JAMA"},{"issue":"12","key":"2024020509071492300_ref11","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jama.2011.336","article-title":"Association of episodic physical and sexual activity with triggering of acute cardiac events: systematic review and meta-analysis","volume":"305","author":"Dahabreh","year":"2011","journal-title":"JAMA"},{"issue":"10","key":"2024020509071492300_ref12","doi-asserted-by":"crossref","first-page":"e79342","DOI":"10.1371\/journal.pone.0079342","article-title":"Energy expenditure during sexual activity in young healthy couples","volume":"8","author":"Frappier","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"2024020509071492300_ref13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000499249","article-title":"Is the history of erectile dysfunction a reliable risk factor for new onset acute myocardial infarction? A systematic review and meta-analysis","volume":"14","author":"Adam","year":"2020","journal-title":"Curr Urol"},{"issue":"1","key":"2024020509071492300_ref14","doi-asserted-by":"crossref","first-page":"e1001372","DOI":"10.1371\/journal.pmed.1001372","article-title":"Erectile dysfunction severity as a risk marker for cardiovascular disease hospitalisation and all-cause mortality: a prospective cohort study","volume":"10","author":"Banks","year":"2013","journal-title":"PLoS Med"},{"issue":"1","key":"2024020509071492300_ref15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1743-6109.2009.01576.x","article-title":"Erectile dysfunction as a predictor for subsequent atherosclerotic cardiovascular events: findings from a linked-data study","volume":"7","author":"Chew","year":"2010","journal-title":"J Sex Med"},{"issue":"21","key":"2024020509071492300_ref16","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2007.10.069","article-title":"Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors","volume":"51","author":"Gazzaruso","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2024020509071492300_ref17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4065\/84.2.108","article-title":"A population-based, longitudinal study of erectile dysfunction and future coronary artery disease","volume":"84","author":"Inman","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"22","key":"2024020509071492300_ref18","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehl142","article-title":"Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial","volume":"27","author":"Montorsi","year":"2006","journal-title":"Eur Heart J"},{"issue":"1","key":"2024020509071492300_ref19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/sj.ijir.3901604","article-title":"Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen study","volume":"20","author":"Schouten","year":"2008","journal-title":"Int J Impot Res"},{"issue":"23","key":"2024020509071492300_ref20","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1001\/jama.294.23.2996","article-title":"Erectile dysfunction and subsequent cardiovascular disease","volume":"294","author":"Thompson","year":"2005","journal-title":"JAMA"},{"issue":"5","key":"2024020509071492300_ref21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.118.033990","article-title":"Erectile dysfunction as an independent predictor of future cardiovascular events: the multi-ethnic study of atherosclerosis","volume":"138","author":"Uddin","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"2024020509071492300_ref22","first-page":"167","article-title":"Erectile dysfunction and essential hypertension: the same aging-related disorder?","volume":"16","author":"Clavijo","year":"2014","journal-title":"Rev Urol"},{"key":"2024020509071492300_ref23","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081848","article-title":"Endothelial dysfunction, erectile deficit and cardiovascular disease: an overview of the pathogenetic links","author":"De Leonardis","year":"2022"},{"issue":"24","key":"2024020509071492300_ref24","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1001\/jama.291.24.2978","article-title":"Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial","volume":"291","author":"Esposito","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"2024020509071492300_ref25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2015.12.048","article-title":"Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"70","author":"Gacci","year":"2016","journal-title":"Eur Urol"},{"key":"2024020509071492300_ref26","volume-title":"Military Medicine","author":"Way","year":"2023"},{"issue":"3","key":"2024020509071492300_ref27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/09540121.2019.1653443","article-title":"Factors associated with erectile dysfunction among men living with HIV: a systematic review","volume":"32","author":"Huntingdon","year":"2020","journal-title":"AIDS Care"},{"issue":"4","key":"2024020509071492300_ref28","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40618-022-01945-w","article-title":"Prevalence and risk factors of erectile dysfunction in COVID-19 patients: a systematic review and meta-analysis","volume":"46","author":"Zhang","year":"2023","journal-title":"J Endocrinol Investig"},{"issue":"4","key":"2024020509071492300_ref29","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/00006842-199807000-00011","article-title":"The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts male aging study","volume":"60","author":"Araujo","year":"1998","journal-title":"Psychosom Med"},{"issue":"10","key":"2024020509071492300_ref30","article-title":"Erectile dysfunction is a hallmark of cardiovascular disease: Unavoidable matter of fact or opportunity to improve men's health?","volume":"10","year":"2021","journal-title":"Clin Med"},{"issue":"3","key":"2024020509071492300_ref31","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/jsm.12792","article-title":"Newly diagnosed erectile dysfunction and risk of depression: a population-based 5-year follow-up study in Taiwan","volume":"12","author":"Chou","year":"2015","journal-title":"J Sex Med"},{"issue":"11","key":"2024020509071492300_ref32","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2337\/diacare.28.11.2637","article-title":"Longitudinal assessment of quality of life in patients with type 2 diabetes and self-reported erectile dysfunction","volume":"28","author":"De Berardis","year":"2005","journal-title":"Diabetes Care"},{"issue":"4","key":"2024020509071492300_ref33","doi-asserted-by":"crossref","first-page":"e13078","DOI":"10.1111\/ijcp.13078","article-title":"Real-world observational results from a database of 48 million men in the United States: relationship of cardiovascular disease, diabetes mellitus and depression with age and erectile dysfunction","volume":"72","author":"Goldstein","year":"2018","journal-title":"Int J Clin Pract"},{"issue":"2","key":"2024020509071492300_ref34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jsxm.2021.11.011","article-title":"The temporal Association of Depression and Anxiety in young men with erectile dysfunction","volume":"19","author":"Manalo","year":"2022","journal-title":"J Sex Med"},{"issue":"12","key":"2024020509071492300_ref35","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.jsxm.2021.09.016","article-title":"Erectile dysfunction is a modifiable risk factor for major depressive disorder: analysis of a federated research network","volume":"18","author":"Nackeeran","year":"2021","journal-title":"J Sex Med"},{"issue":"5","key":"2024020509071492300_ref36","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1185\/030079904125003467","article-title":"The multinational Men's attitudes to life events and sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population","volume":"20","author":"Rosen","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"2024020509071492300_ref37","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1743-6109.2005.20354.x","article-title":"Relationships between erectile dysfunction, depression, and anxiety in Japanese subjects","volume":"2","author":"Sugimori","year":"2005","journal-title":"J Sex Med"},{"issue":"8","key":"2024020509071492300_ref38","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jsxm.2018.05.016","article-title":"Erectile dysfunction and depression: A systematic review and meta-analysis","volume":"15","author":"Liu","year":"2018","journal-title":"J Sex Med"},{"issue":"2","key":"2024020509071492300_ref39","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.juro.2006.09.030","article-title":"Bidirectional relationship between depression and erectile dysfunction","volume":"177","author":"Shiri","year":"2007","journal-title":"J Urol"},{"issue":"6","key":"2024020509071492300_ref40","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/j.1743-6109.2012.02709.x","article-title":"Bidirectional association between depression and sexual dysfunction: a systematic review and meta-analysis","volume":"9","author":"Atlantis","year":"2012","journal-title":"J Sex Med"},{"issue":"2","key":"2024020509071492300_ref41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0090-4295(02)01691-6","article-title":"Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression","volume":"60","author":"Nurnberg","year":"2002","journal-title":"Urology"},{"issue":"1","key":"2024020509071492300_ref42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1176\/appi.ajp.163.1.79","article-title":"Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study","volume":"163","author":"Rosen","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"4","key":"2024020509071492300_ref43","article-title":"Erectile dysfunction in young men \u2013 A review of the prevalence and risk factors.","volume":"5","year":"2017","journal-title":"Sex Med Rev"},{"issue":"5","key":"2024020509071492300_ref44","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/01.CIR.0000136993.34344.41","article-title":"Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham heart study","volume":"110","author":"Fox","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"2024020509071492300_ref45","article-title":"Heart disease and stroke statistics\u20142013 update: a report from the American Heart Association","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"2024020509071492300_ref46","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/archinte.1972.00320050038003","article-title":"Epidemiology of sudden death","volume":"129","author":"Kuller","year":"1972","journal-title":"Arch Intern Med"},{"issue":"11 Suppl 1","key":"2024020509071492300_ref47","first-page":"I3","article-title":"Epidemiology and stratification of risk for sudden cardiac death","volume":"28","author":"Podrid","year":"2005","journal-title":"Clin Cardiol"},{"issue":"1","key":"2024020509071492300_ref48","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ahj.2008.08.016","article-title":"Trends from 1987 to 2004 in sudden death due to coronary heart disease: the atherosclerosis risk in communities (ARIC) study","volume":"157","author":"Ni","year":"2009","journal-title":"Am Heart J"},{"issue":"8","key":"2024020509071492300_ref49","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jacc.2003.11.041","article-title":"Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo study","volume":"43","author":"Fung","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2024020509071492300_ref50","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/archinte.166.2.213","article-title":"The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease","volume":"166","author":"Grover","year":"2006","journal-title":"Arch Intern Med"},{"issue":"2 Pt 2","key":"2024020509071492300_ref51","first-page":"S46","article-title":"Erectile dysfunction in the cardiac patient: how common and should we treat?","volume":"170","author":"Kloner","year":"2003","journal-title":"J Urol"},{"issue":"8","key":"2024020509071492300_ref52","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1253\/circj.67.656","article-title":"Men's Health Study: Epidemiology of erectile dysfunction and cardiovascular disease","volume":"67","author":"Sasayama","year":"2003","journal-title":"Circ J"},{"issue":"2","key":"2024020509071492300_ref53","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(02)03113-2","article-title":"Relation of erectile dysfunction to angiographic artery disease","volume":"91","author":"Solomon","year":"2003","journal-title":"Am J Cardiol"},{"issue":"9","key":"2024020509071492300_ref54","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/j.1743-6109.2009.01354.x","article-title":"Erectile dysfunction and mortality","volume":"6","author":"Araujo","year":"2009","journal-title":"J Sex Med"},{"issue":"3","key":"2024020509071492300_ref55","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.ijir.3900282","article-title":"Does severity of ischemic coronary disease correlate with erectile function?","volume":"9","author":"Greenstein","year":"1997","journal-title":"Int J Impot Res"},{"issue":"3","key":"2024020509071492300_ref56","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.amjmed.2013.10.013","article-title":"All men with vasculogenic erectile dysfunction require a cardiovascular workup","volume":"127","author":"Miner","year":"2014","journal-title":"Am J Med"},{"issue":"1","key":"2024020509071492300_ref57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ahj.2012.04.006","article-title":"Prognostic utility of erectile dysfunction for cardiovascular disease in younger men and those with diabetes","volume":"164","author":"Miner","year":"2012","journal-title":"Am Heart J"},{"issue":"5","key":"2024020509071492300_ref58","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/j.1743-6109.2011.02224.x","article-title":"Erectile dysfunction and coronary artery disease: an association of higher risk in younger men","volume":"8","author":"Riedner","year":"2011","journal-title":"J Sex Med"},{"key":"2024020509071492300_ref59","volume-title":"A Dictionary of Epidemiology","author":"Porta","year":"2016","edition":"6th"},{"issue":"1","key":"2024020509071492300_ref60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/1358863X17725809","article-title":"The relationship of erectile dysfunction and subclinical cardiovascular disease","volume":"23","author":"Osondo","year":"2018","journal-title":"A systematic review and meta-analysis. Vasc Med"},{"issue":"4","key":"2024020509071492300_ref61","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jacc.2009.08.058","article-title":"Does erectile dysfunction contribute to cardiovascular disease risk prediction beyond the Framingham risk score?","volume":"55","author":"Araujo","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2024020509071492300_ref62","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4314\/gmj.v57i1.7","article-title":"Association of erectile dysfunction with coronary artery disease in type 2 diabetes mellitus","volume":"57","author":"Dsouza","year":"2023","journal-title":"Ghana Med J"},{"issue":"12","key":"2024020509071492300_ref63","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/CIRCULATIONAHA.109.864199","article-title":"Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: the ongoing Telmisartan alone and in combination with Ramipril global endpoint trial\/Telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease (ONTARGET\/TRANSCEND) trials","volume":"121","author":"Bohm","year":"2010","journal-title":"Circulation"},{"issue":"3","key":"2024020509071492300_ref64","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.eururo.2005.05.014","article-title":"Is erectile dysfunction an indicator for increased risk of coronary heart disease and stroke?","volume":"48","author":"Ponholzer","year":"2005","journal-title":"Eur Urol"},{"issue":"13","key":"2024020509071492300_ref65","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jacc.2011.06.024","article-title":"Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies","volume":"58","author":"Dong","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2024020509071492300_ref66","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1111\/j.1743-6109.2010.01792.x","article-title":"Erectile dysfunction and risk of clinical cardiovascular events: a meta-analysis of seven cohort studies","volume":"7","author":"Guo","year":"2010","journal-title":"J Sex Med"},{"issue":"May 23","key":"2024020509071492300_ref67","doi-asserted-by":"crossref","first-page":"j2099","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"issue":"3","key":"2024020509071492300_ref68","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nrcardio.2013.216","article-title":"Risk factors: new risk assessment guidelines: more or less personalized","volume":"11","author":"Blaha","year":"2014","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"2024020509071492300_ref69","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3949\/ccjm.87a.19078","article-title":"ACC\/AHA guidelines: personalized care to prevent cardiovascular disease","volume":"87","author":"Brennan","year":"2020","journal-title":"Cleve Clin J Med"},{"issue":"3","key":"2024020509071492300_ref70","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.amjmed.2015.08.038","article-title":"Cardiovascular disease prevention in men with vascular erectile dysfunction: the view of the preventative cardiologist","volume":"129","author":"Shah","year":"2016","journal-title":"Am J Med"},{"issue":"8","key":"2024020509071492300_ref71","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2012.9624","article-title":"Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals","volume":"308","author":"Yeboah","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"2024020509071492300_ref72","first-page":"34","article-title":"Relationship of sexual activity and the heart in the aging male: use of the Princeton consensus panel guidelines for practical therapy","volume":"17","author":"Miner","year":"2009","journal-title":"Clin Geriatr"},{"issue":"3","key":"2024020509071492300_ref73","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.juro.2018.05.004","article-title":"Erectile dysfunction: AUA guideline","volume":"200","author":"Burnett","year":"2018","journal-title":"J Urol"},{"issue":"8","key":"2024020509071492300_ref74","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIR.0b013e3182447787","article-title":"Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"125","author":"Levine","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"2024020509071492300_ref75","first-page":"242","article-title":"Update on the safety of phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. Sex","volume":"6","author":"Yafi","year":"2018","journal-title":"Med Rev"},{"issue":"3","key":"2024020509071492300_ref76","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11930-008-0024-7","article-title":"Combination therapy with phosphodiesterase type V inhibitors and testosterone","volume":"5","author":"Buvat","year":"2008","journal-title":"Curr Sex Health Rep"},{"issue":"1","key":"2024020509071492300_ref77","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1743-6109.2010.01956.x","article-title":"Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study)","volume":"8","author":"Buvat","year":"2011","journal-title":"J Sex Med"},{"issue":"1","key":"2024020509071492300_ref78","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1743-6109.2009.01458.x","article-title":"Effects of weight loss intervention on erectile dysfunction in older men with type 2 diabetes in the look AHEAD trial","volume":"7","author":"Wing","year":"2010","journal-title":"J Sex Med"},{"issue":"11","key":"2024020509071492300_ref79","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1111\/j.1743-6109.2009.01432.x","article-title":"Erectile dysfunction (ED) is a shared sexual concern of couples II: association of female partner characteristics with male partner ED treatment seeking and phosphodiesterase type 5 inhibitor utilization","volume":"6","author":"Fisher","year":"2009","journal-title":"J Sex Med"},{"issue":"1105","key":"2024020509071492300_ref80","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1136\/postgradmedj-2016-134073","article-title":"Recent advances in the treatment of erectile dysfunction","volume":"93","author":"Mobley","year":"2017","journal-title":"Postgrad Med J"},{"issue":"suppl 1","key":"2024020509071492300_ref81","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1038\/sj.ijir.3900800","article-title":"The role of the partner in erectile dysfunction and its treatment","volume":"14","author":"Riley","year":"2002","journal-title":"Int J Impot Res"},{"issue":"1","key":"2024020509071492300_ref82","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1742-1241.2007.01634.x","article-title":"When treating erectile dysfunction, do not forget the partner","volume":"62","author":"Riley","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"12 Suppl","key":"2024020509071492300_ref83","first-page":"S639","article-title":"Partner and relationship issues in the treatment of erectile dysfunction","volume":"6","author":"Westheimer","year":"2000","journal-title":"Am J Manag Care"},{"issue":"2","key":"2024020509071492300_ref84","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2215025","article-title":"Cardiovascular safety of testosterone-replacement therapy","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"2024020509071492300_ref85","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1517\/14656566.2015.1052742","article-title":"Use of nitrates in ischemic heart disease","volume":"16","author":"Giusseppe","year":"2015","journal-title":"Exp Opin Pharmacother"},{"issue":"3 Pt 1","key":"2024020509071492300_ref86","first-page":"577","article-title":"Long-term nitrate use may be deleterious in ischemic heart disease. A study using the database from two large postinfarction studies","volume":"138","author":"Nakamura","year":"1999","journal-title":"Multicenter Myocardial Ischemia Research Group. Am Heart J"},{"issue":"2","key":"2024020509071492300_ref87","article-title":"The role of organic nitrates in the optimal medical management of angina","volume":"15","author":"Soman","year":"2017","journal-title":"e-J Card Pract"},{"issue":"8","key":"2024020509071492300_ref88","first-page":"CD011205","article-title":"Guanylate cyclase stimulators for pulmonary hypertension","volume":"2016","author":"Wardle","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2024020509071492300_ref89","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0021-9258(19)86221-X","article-title":"Characterization of a novel cGMP binding protein from rat lung","volume":"255","author":"Francis","year":"1980","journal-title":"J Biol Chem1980"},{"issue":"8","key":"2024020509071492300_ref90","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1073\/pnas.73.8.2559","article-title":"Guanosine 3':5'-cyclic monophosphate binding proteins in rat tissues","volume":"73","author":"Lincoln","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"2024020509071492300_ref91","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"issue":"20","key":"2024020509071492300_ref92","doi-asserted-by":"crossref","first-page":"13729","DOI":"10.1074\/jbc.274.20.13729","article-title":"Cyclic GMP phosphodiesterase-5: target of sildenafil","volume":"274","author":"Corbin","year":"1999","journal-title":"J Biol Chem"},{"issue":"12","key":"2024020509071492300_ref93","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00210-017-1429-5","article-title":"Meeting report of the 8th international conference on cGMP \u201ccGMP: generators, effectors, and therapeutic implications\u201d at Bamberg, Germany, from June 23 to 25, 2017","volume":"390","author":"Friebe","year":"2017","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"5","key":"2024020509071492300_ref94","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.bjp.0707132","article-title":"Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase","volume":"150","author":"Kukreja","year":"2007","journal-title":"Br J Pharmcol"},{"issue":"49","key":"2024020509071492300_ref95","doi-asserted-by":"crossref","first-page":"47581","DOI":"10.1074\/jbc.M206088200","article-title":"Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity","volume":"277","author":"Francis","year":"2002","journal-title":"J Biol Chem"},{"issue":"2","key":"2024020509071492300_ref96","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1124\/jpet.107.126540","article-title":"Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors","volume":"323","author":"Blount","year":"2007","journal-title":"J Pharmcol Exp Ther"},{"issue":"1","key":"2024020509071492300_ref97","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/jsm.12023","article-title":"SOP conservative (medical and mechanical) treatment of erectile dysfunction","volume":"10","author":"Porst","year":"2013","journal-title":"J Sex Med"},{"issue":"1","key":"2024020509071492300_ref98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ijir.2009.29","article-title":"Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success","volume":"22","author":"Shabsigh","year":"2010","journal-title":"Int J Impot Res"},{"issue":"1","key":"2024020509071492300_ref99","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/and.12216","article-title":"Efficacy and safety of long-term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction","volume":"47","author":"Cui","year":"2015","journal-title":"Andrologia"},{"issue":"12B","key":"2024020509071492300_ref100","article-title":"Phosphodiesterase 5 mechanisms and therapeutic applications","volume":"96","author":"Burnett","year":"2005","journal-title":"Am J Cardiol"},{"issue":"8","key":"2024020509071492300_ref101","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1742-1241.2009.02119.x","article-title":"Toward a new \u2018EPOCH\u2019: optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction","volume":"63","author":"Sadovsky","year":"2009","journal-title":"Int J Clin Pract"},{"issue":"6","key":"2024020509071492300_ref102","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1111\/andr.12866","article-title":"Testosterone positively regulates functional responses and nitric oxide expression in the isolated human corpus cavernosum","volume":"8","author":"Gur","year":"2020","journal-title":"Andrology"},{"issue":"2 Suppl 2","key":"2024020509071492300_ref103","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0090-4295(02)01688-6","article-title":"Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction","volume":"60","author":"McCullough","year":"2002","journal-title":"Urology"},{"issue":"3","key":"2024020509071492300_ref104","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40266-018-0528-4","article-title":"Non-invasive management options for erectile dysfunction when a phosphodiesterase type 5 inhibitor fails","volume":"35","author":"Lee","year":"2018","journal-title":"Drugs Aging"},{"issue":"9","key":"2024020509071492300_ref105","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1111\/j.1743-6109.2009.01364.x","article-title":"Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction","volume":"6","author":"Canguven","year":"2009","journal-title":"J Sex Med"},{"issue":"3","key":"2024020509071492300_ref106","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4081\/aiua.2015.3.204","article-title":"PDE-5 inhibitors in monotherapy verses combination therapy in a sample of 1200 patients with erectile dysfunction","volume":"87","author":"Labairu-Huerta","year":"2015","journal-title":"Arch Ital Urol Androl"},{"issue":"1","key":"2024020509071492300_ref107","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0735-1097(98)00656-1","article-title":"ACC\/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease","volume":"33","author":"Cheitlin","year":"1999","journal-title":"American College of Cardiology\/American Heart Association. J Am Coll Cardiol"},{"issue":"10","key":"2024020509071492300_ref108","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jacc.2003.09.023","article-title":"Time course of the interaction between tadalafil and nitrates","volume":"42","author":"Kloner","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2024020509071492300_ref109","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2125.2009.03375.x","article-title":"Time-dependent interactions of the hypotensive effects of sildenafil citrate and sublingual glyceryl trinitrate","volume":"67","author":"Oliver","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"2024020509071492300_ref110","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1097\/01.CCM.0000269371.70738.30","article-title":"Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial","volume":"35","author":"Parker","year":"2007","journal-title":"Crit Care Med"},{"issue":"212248","key":"2024020509071492300_ref111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212248","article-title":"Hemodynamic effect of avanafil and glyceryl trinitrate coadministration","volume":"2013","author":"Swearingen","year":"2013","journal-title":"Drugs Context"},{"issue":"5A","key":"2024020509071492300_ref112","article-title":"Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist","volume":"83","author":"Webb","year":"1999","journal-title":"Am J Cardiol"},{"issue":"1","key":"2024020509071492300_ref113","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0735-1097(00)00705-1","article-title":"Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina","volume":"36","author":"Webb","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2024020509071492300_ref114","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/cpt.759","article-title":"Evaluation of pharmacokinetic and pharmacodynamic drug-drug interaction of Sacubitril\/valsartan (LCZ696) and sildenafil in patients with mild-to-moderate hypertension","volume":"103","author":"Hsiao","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2024020509071492300_ref115","first-page":"88","article-title":"Neprilysin inhibitors in heart failure: the science, mechanism of action, clinical studies, and unanswered questions","volume":"8","author":"Bozkurt","year":"2023","journal-title":"J Am Coll Cardiol Basic Trans Science"},{"issue":"1","key":"2024020509071492300_ref116","doi-asserted-by":"crossref","DOI":"10.1136\/thoraxjnl-2015-207170","article-title":"The molecular targets of approved treatments for pulmonary arterial hypertension","volume":"71","author":"Humbert","year":"2016","journal-title":"Thorax"},{"issue":"1","key":"2024020509071492300_ref117","first-page":"2045894019837849","article-title":"EXPRESS: switching to riociguat: A potential treatment strategy for the management of CTEPH and PAH","volume":"10","author":"Benza","year":"2019","journal-title":"Pulm Circ"},{"issue":"8","key":"2024020509071492300_ref118","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s11255-020-02454-6","article-title":"The hemodynamic interactions of combination therapy with alpha-blockers and phosphodiesterase-5 inhibitors compared to monotherapy with alpha-blockers: a systematic review and meta-analysis","volume":"52","author":"Adamou","year":"2020","journal-title":"Int Urol Nephrol"},{"issue":"12B","key":"2024020509071492300_ref119","doi-asserted-by":"crossref","first-page":"42M","DOI":"10.1016\/j.amjcard.2005.07.011","article-title":"Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions","volume":"96","author":"Kloner","year":"2005","journal-title":"Am J Cardiol"},{"issue":"5 Pt 1","key":"2024020509071492300_ref120","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1097\/01.ju.0000142687.75577.e4","article-title":"Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men","volume":"172","author":"Kloner","year":"2004","journal-title":"J Urol"},{"issue":"5","key":"2024020509071492300_ref121","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1350-9462(02)00013-7","article-title":"Viagra, sildenafil citrate and ophthalmology","volume":"21","author":"Laties","year":"2002","journal-title":"Prog Retin Eye Res"},{"key":"2024020509071492300_ref122","author":"Viagra"},{"issue":"1","key":"2024020509071492300_ref123","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/eye.2014.144","article-title":"Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy","volume":"29","author":"Miller","year":"2015","journal-title":"Eye (Lond)"},{"issue":"2","key":"2024020509071492300_ref124","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/WNO.0000000000000299","article-title":"The relationship between phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy","volume":"36","author":"Pomeranz","year":"2016","journal-title":"J Neuroophthalmol"},{"issue":"5","key":"2024020509071492300_ref125","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jamaophthalmol.2022.0663","article-title":"Risk of ocular adverse events associated with use of phosphodiesterase 5 inhibitors in men in the US","volume":"140","author":"Etminan","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"2024020509071492300_ref126","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/lary.20511","article-title":"Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology","volume":"119","author":"Maddox","year":"2009","journal-title":"Laryngoscope"},{"issue":"3","key":"2024020509071492300_ref127","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/MAO.0000000000002148","article-title":"Phosphodiesterase-5 (PDE5) inhibitor and ototoxicity: A systematic review","volume":"40","author":"Manna","year":"2019","journal-title":"Otol Neurotol Mar"},{"key":"2024020509071492300_ref128","doi-asserted-by":"crossref","first-page":"102251","DOI":"10.1016\/j.canep.2022.102251","article-title":"Use of phosphodiesterase-5 inhibitors and the incidence of melanoma","volume":"81","author":"Wayne","year":"2022","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"2024020509071492300_ref129","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.eururo.2015.02.002","article-title":"A detailed analysis of the association between postoperative phosphodiesterase type 5 inhibitor use and risk of biochemical recurrence after radical prostatectomy","volume":"68","author":"Gallina","year":"2015","journal-title":"Eur Urol Nov"},{"issue":"5","key":"2024020509071492300_ref130","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.eururo.2015.12.013","article-title":"Phosphodiesterase type 5 inhibitor use and disease recurrence after prostate cancer treatment","volume":"70","author":"Loeb","year":"2016","journal-title":"Eur Urol Nov"},{"issue":"2","key":"2024020509071492300_ref131","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.juro.2014.08.111","article-title":"Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy","volume":"193","author":"Michl","year":"2015","journal-title":"J Urol"},{"issue":"2","key":"2024020509071492300_ref132","doi-asserted-by":"crossref","first-page":"57.e1","DOI":"10.1016\/j.urolonc.2021.05.031","article-title":"The association of phosphodiesterase-5 inhibitors with the biochemical recurrence-free and overall survival of patients with prostate cancer following radial prostatectomy","volume":"40","author":"Danley","year":"2022","journal-title":"Urol Oncol"},{"issue":"8","key":"2024020509071492300_ref133","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.2337\/diacare.25.8.1336","article-title":"Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilation in type 2 diabetes","volume":"25","author":"Desouza","year":"2002","journal-title":"Diabetes Care"},{"issue":"2","key":"2024020509071492300_ref134","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2004.10.002","article-title":"Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk","volume":"47","author":"Rosano","year":"2005","journal-title":"Eur Urol"},{"issue":"21","key":"2024020509071492300_ref135","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/heartjnl-2015-309223","article-title":"Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality","volume":"102","author":"Anderson","year":"2016","journal-title":"Heart"},{"issue":"3","key":"2024020509071492300_ref136","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4239\/wjd.v8.i3.104","article-title":"Statin, testosterone and phosphodiesterase 5- inhibitor treatments and age related mortality in diabetes","volume":"8","author":"Hackett","year":"2017","journal-title":"World J Diabetes"},{"issue":"16","key":"2024020509071492300_ref137","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/heartjnl-2016-310746","article-title":"Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction","volume":"103","author":"Andersson","year":"2017","journal-title":"Heart"},{"issue":"12","key":"2024020509071492300_ref138","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.jacc.2021.01.045","article-title":"Association of phosphodiesterase-5 inhibitors versus alprostadil with survival in men with coronary artery disease","volume":"77","author":"Andersson","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2024020509071492300_ref139","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1007\/s00345-022-04005-3","article-title":"Is tadalafil associated with decreased risk of major adverse cardiac events or venous thromboembolism in men with lower urinary tract symptoms?","volume":"40","author":"Goberdhan","year":"2022","journal-title":"World J Urol"},{"issue":"11","key":"2024020509071492300_ref140","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3899\/jrheum.201226","article-title":"Erectile dysfunction and cardiovascular risk in men with rheumatoid arthritis: A population-based cohort study","volume":"48","author":"Wilton","year":"2021","journal-title":"J Rheumatol"},{"issue":"14","key":"2024020509071492300_ref141","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1177\/2047487317718082","article-title":"Relationship between treatment of erectile dysfunction and future risk of cardiovascular disease: A nationwide cohort study. Eur","volume":"24","author":"Vestergaard","year":"2017","journal-title":"J Prev Cardiol"},{"issue":"1","key":"2024020509071492300_ref142","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/jsxmed\/qdac005","article-title":"Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction and cardiovascular risk factors: A retrospective, observational study based on healthcare claims and national death index data","volume":"20","author":"Kloner","year":"2023","journal-title":"J Sex Med"},{"issue":"1","key":"2024020509071492300_ref143","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jsxm.2021.10.012","article-title":"Retrospective observational real-world outcome study to evaluate safety among patients with erectile dysfunction (ED) with co-possession of tadalafil and anti-hypertensive medications (anti-HTN).","volume":"19","author":"Nunes","year":"2022","journal-title":"J Sex Med"},{"issue":"16","key":"2024020509071492300_ref144","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1056\/NEJMsa1504267","article-title":"Emergency department visits for adverse events related to dietary supplements","volume":"373","author":"Geller","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"2024020509071492300_ref145","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.3337","article-title":"Unapproved pharmaceutical ingredients included in dietary supplements associated with US Food and Drug Administration warnings","volume":"1","author":"Tucker","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2024020509071492300_ref146","doi-asserted-by":"crossref","first-page":"e13849","DOI":"10.1111\/ijcp.13849","article-title":"Increasing access to erectile dysfunction treatment via pharmacies to improve healthcare provider visits and quality of life: results from a prospective real-world observational study in the United Kingdom","volume":"75","author":"Lee","year":"2021","journal-title":"Int J Clin Prac"},{"issue":"2","key":"2024020509071492300_ref147","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1743-6109.2012.02998.x","article-title":"Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management","volume":"10","author":"Scranton","year":"2013","journal-title":"J Sex Med"},{"issue":"8","key":"2024020509071492300_ref148","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41443-021-00456-1","article-title":"The use of combination regenerative therapies for erectile dysfunction: rationale and current status","volume":"34","author":"Towe","year":"2022","journal-title":"Int J Impot Res"},{"issue":"2","key":"2024020509071492300_ref149","doi-asserted-by":"crossref","first-page":"15579883221087532","DOI":"10.1177\/15579883221087532","article-title":"Systematic review and meta-analysis of 16 randomized controlled trials of clinical outcomes of low-intensity extracorporeal shock wave therapy in treating erectile dysfunction","volume":"16","author":"Yao","year":"2022","journal-title":"Am J Mens Health"},{"issue":"2","key":"2024020509071492300_ref150","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.47391\/JPMA.AKUS-11","article-title":"Stem cells in urology","volume":"73(Suppl 1)","author":"Nazim","year":"2023","journal-title":"J Pak Med Assoc"},{"issue":"1","key":"2024020509071492300_ref151","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/aja.2011.79","article-title":"Stem cells: novel players in the treatment of erectile dysfunction","volume":"14","author":"Zhang","year":"2012","journal-title":"Asian J Androl"},{"key":"2024020509071492300_ref152","doi-asserted-by":"crossref","first-page":"944765","DOI":"10.3389\/frph.2022.944765","article-title":"Erectile dysfunction: is platelet-rich plasma the new frontier for treatment in patients with erectile dysfunction? A review of the existing evidence","volume":"4","author":"Anastasiadis","year":"2022  16","journal-title":"Front Reprod Health"},{"issue":"4","key":"2024020509071492300_ref153","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41443-021-00482-z","article-title":"The potential of platelet-rich plasma injections and stem cell therapy for penile rejuvenation","volume":"34","author":"Israeli","year":"2022","journal-title":"Int J Impot Res"},{"issue":"1","key":"2024020509071492300_ref154","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000003481","article-title":"Platelet-rich plasma for the treatment of erectile dysfunction: A prospective, randomized, double-blind, placebo-controlled clinical trial.","volume":"210","author":"Masterson","year":"2023","journal-title":"J Urol"},{"issue":"1","key":"2024020509071492300_ref155","first-page":"8","article-title":"Efficacy and safety of low-intensity extracorporeal shockwave therapy for treatment of vascular erectile dysfunction in Nigerian men: report of A study in Ibadan, south-West Nigeria","volume":"19","author":"Akande","year":"2021","journal-title":"Ann Ibadan Postgrad Med"},{"issue":"2","key":"2024020509071492300_ref156","doi-asserted-by":"crossref","first-page":"e14324","DOI":"10.1111\/and.14324","article-title":"A single-Centre result of two courses of low-intensity shockwave therapy (Li-SWT) in erectile dysfunction","volume":"54","author":"Geyik","year":"2022","journal-title":"Andrologia"},{"issue":"9","key":"2024020509071492300_ref157","doi-asserted-by":"crossref","first-page":"e14518","DOI":"10.1111\/and.14518","article-title":"Early outcomes of short-course low intensity shockwave therapy (LiSWT) for erectile dysfunction: A prospective, randomized, double-blinded, sham-controlled study in Malaysia","volume":"54","author":"Ong","year":"2022","journal-title":"Andrologia"},{"issue":"1","key":"2024020509071492300_ref158","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jsxm.2015.11.008","article-title":"Low-energy shock wave therapy ameliorates erectile dysfunction in a pelvic neurovascular injuries rat model","volume":"13","author":"Li","year":"2016","journal-title":"J Sex Med"},{"issue":"4","key":"2024020509071492300_ref159","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jsxm.2017.02.004","article-title":"In situ activation of penile progenitor cells with low-intensity extracorporeal shockwave therapy","volume":"14","author":"Lin","year":"2017","journal-title":"J Sex Med"},{"issue":"12","key":"2024020509071492300_ref160","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.jsxm.2019.08.020","article-title":"Smooth muscle differentiation of penile stem\/progenitor cells induced by microenergy acoustic pulses in vitro","volume":"16","author":"Peng","year":"2019","journal-title":"J Sex Med"},{"issue":"9","key":"2024020509071492300_ref161","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.jsxm.2020.05.018","article-title":"Exosome released from Schwann cells may be involved in microenergy acoustic pulse-associated cavernous nerve regeneration","volume":"17","author":"Peng","year":"2020","journal-title":"J Sex Med"},{"key":"2024020509071492300_ref162","article-title":"News and future perspectives of non-surgical treatments for erectile dysfunction","author":"Manfredi","year":"2022  27","journal-title":"Int J Impot Res"},{"issue":"8304","key":"2024020509071492300_ref163","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0140-6736(82)90910-2","article-title":"Intracavernous papaverine for erectile failure","volume":"2","author":"Virag","year":"1982  23","journal-title":"Lancet"},{"issue":"4","key":"2024020509071492300_ref164","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1192\/bjp.143.4.332","article-title":"Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence","volume":"143","author":"Brindley","year":"1983","journal-title":"Br J Psychiatry"},{"issue":"1","key":"2024020509071492300_ref165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199701023360101","article-title":"Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated urethral system for erection (MUSE) study group","volume":"336","author":"Padma-Nathan","year":"1997","journal-title":"N Engl J Med"},{"issue":"2","key":"2024020509071492300_ref166","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jsxm.2017.12.003","article-title":"Efficacy and safety of MED2005, a topical glyceryl Trinitrate formulation, in the treatment of erectile dysfunction: A randomized crossover study","volume":"15","author":"Ralph","year":"2018","journal-title":"J Sex Med"},{"issue":"1","key":"2024020509071492300_ref167","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1742-1241.2007.01636.x","article-title":"Integrating partners into erectile dysfunction treatment: improving the sexual experience for the couple","volume":"62","author":"Dean","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"5","key":"2024020509071492300_ref168","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.mayocp.2019.01.009","article-title":"The International Society for the Study of Women's sexual health process of Care for the Identification of sexual concerns and problems in women","volume":"94","author":"Parish","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2024020509071492300_ref169","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1089\/152460902317586001","article-title":"Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder","volume":"11","author":"Basson","year":"2002","journal-title":"J Womens Health Gend Based Med"},{"issue":"2","key":"2024020509071492300_ref170","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ijgo.2015.08.015","article-title":"Systematic review and meta-analysis of phosphodiesterase type 5 inhibitors for the treatment of female sexual dysfunction","volume":"133","author":"Gao","year":"2016","journal-title":"Int J Gynaecol Obstet"},{"issue":"4","key":"2024020509071492300_ref171","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jama.300.4.395","article-title":"Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial","volume":"300","author":"Nurnberg","year":"2008","journal-title":"JAMA"},{"issue":"6","key":"2024020509071492300_ref172","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0090-4295(00)00493-3","article-title":"Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury","volume":"55","author":"Sipski","year":"2000","journal-title":"Urology"},{"key":"2024020509071492300_ref173","author":"Adcirca (tadalafil); Package insert.","year":"2020"},{"key":"2024020509071492300_ref174","volume-title":"Revatio (Sildenafil), Oral Tablet, Oral Suspension, Injectable","year":"2014"},{"issue":"1","key":"2024020509071492300_ref175","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1378\/chest.14-0263","article-title":"Sex differences in response to tadalafil in pulmonary arterial hypertension","volume":"147","author":"Mathai","journal-title":"Chest"},{"issue":"3","key":"2024020509071492300_ref176","doi-asserted-by":"crossref","first-page":"e006389","DOI":"10.1136\/bmjopen-2014-006389","article-title":"Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies","volume":"5","author":"Garner","year":"2015","journal-title":"BMJ Open"},{"key":"2024020509071492300_ref177","article-title":"Part II: the treatment of primary and secondary Raynaud's phenomenon","author":"Curtiss","year":"2022  6","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"2024020509071492300_ref178","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","article-title":"Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials","volume":"72","author":"Roustit","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2024020509071492300_ref179","doi-asserted-by":"crossref","first-page":"694","DOI":"10.7326\/M18-0517","article-title":"On-demand sildenafil as a treatment for Raynaud phenomenon: A series of n-of-1 trials","volume":"169","author":"Roustit","year":"2018","journal-title":"Ann Intern Med"},{"issue":"19","key":"2024020509071492300_ref180","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10194346","article-title":"Sildenafil supplementation for women undergoing infertility treatments: A systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Marin","year":"2021","journal-title":"J Clin Med"},{"issue":"7","key":"2024020509071492300_ref181","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219732","article-title":"The effects of sildenafil in maternal and fetal outcomes in pregnancy: A systematic review and meta-analysis","volume":"14","author":"Ferreira","year":"2019","journal-title":"PLoS One"},{"issue":"11","key":"2024020509071492300_ref182","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/1471-0528.17163","article-title":"Phosphodiesterase-5 inhibitors in pregnancy: systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes","volume":"129","author":"Turner","year":"2022","journal-title":"BJOG"},{"issue":"7","key":"2024020509071492300_ref183","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2527","article-title":"Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the Sil HF study): a randomized placebo-controlled multicentre trial.","volume":"24","author":"Cooper","year":"2022","journal-title":"Eur J Heart Fail"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/21\/2\/90\/56549822\/qdad163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/21\/2\/90\/56549822\/qdad163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T04:09:00Z","timestamp":1707106140000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/21\/2\/90\/7499332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,26]]},"references-count":183,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,12,26]]},"published-print":{"date-parts":[[2024,1,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdad163","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,12,26]]}}}